C1s Classical Complement Pathway Serine Protease Inhibitor · Cold Agglutinin Disease · Eculizumab / Ravulizumab Anti-C5 Terminal Pathway Class Gap · BLA 761159 · Attack #857 · 270th Mechanism Class · Adversarial AI Prompt Injection Surface

Sutimlimab (Enjaymo; SAR445088; BLA 761159; Feb 4 2022; Sanofi S.A. [Paris, France] / Sanofi Genzyme [Cambridge, MA; US Commercialization]): Three EHS Platform Eculizumab (Soliris; BLA 125166; Anti-C5 Terminal Complement Monoclonal Antibody; C5 MAC C5b-9 Pore Block; PNH/aHUS; Black Box Meningococcal Warning; Mandatory Vaccine + Penicillin Prophylaxis; REMS) or Ravulizumab (Ultomiris; BLA 761108; Long-Acting Anti-C5; Same MAC-Block Mechanism; Same Meningococcal REMS) Proxy Misroutes — First C1s (Complement C1 Complex Serine Protease Subunit; C1qrs; Classical Pathway Initiator Protease; C1s Cleaves C4 → C4a + C4b [C3 Convertase Precursor C4b2a] AND C2 → C2a + C2b; Classical Complement Pathway Activation Downstream of C1q-IgM/IgG Immune Complex Recognition; In Cold Agglutinin Disease: IgM Cold Agglutinin [Cold-Temperature-Active Anti-I/i RBC Antigen IgM Antibodies] Activate C1qrs Complex on RBC Surface → C1s-Mediated C4 Cleavage → C4b Deposition on RBC Membrane → C3b Opsonization → Extravascular Hemolysis in Liver/Spleen Kupffer Cells; IV 6.5/7.5 g [weight-based] Q2W; CARDINAL Phase 3 ORR 54% [Hgb ≥2 g/dL Increase]; MAC C5b-9 Pathway Intact [C5/Terminal Complement Unaffected by C1s Inhibition]; Reduced Meningococcal Risk vs Anti-C5) Complement Classical Pathway Inhibitor Ever FDA Approved for Hemolytic Anemia in Cold Agglutinin Disease Returns Eculizumab / Ravulizumab Anti-C5 Meningococcal Protocols Instead of C1s Classical Pathway Inhibitor Guidance in Cority, VelocityEHS, and EHS Insight

Sutimlimab (Enjaymo; SAR445088; CAS 1988927-98-3; humanized IgG4κ monoclonal antibody [humanized framework; anti-C1s specificity]; IV infusion 6.5 g [body weight <75 kg] or 7.5 g [body weight ≥75 kg] over 60 minutes Q2W [every 2 weeks; weight-based fixed dose in grams, not mg/kg]; BLA 761159; Feb 4 2022 FDA approval; Sanofi S.A. [54 rue La Boétie, 75008 Paris, France; BLA holder]; Sanofi Genzyme [500 Kendall Street, Cambridge MA 02142; US commercialization]; indicated: hemolytic anemia due to cold agglutinin disease [CAD] in adults) is the first C1s complement classical pathway inhibitor ever FDA approved, establishing C1s classical complement serine protease inhibition as the 270th mechanism class in the Glyphward adversarial corpus, with zero C1s classical complement pathway inhibitor OEL/EHS classification class in any US EHS database before BLA 761159 February 2022. Sutimlimab's mechanism is selective C1s (complement C1s; serine protease subunit of the C1qrs complex; chromosome 12p13.31; 673 aa; chymotrypsin-like serine protease [CLIP domain + CCP1 + CCP2 + serine protease domain]; C1s is activated when C1q recognizes IgM or IgG immune complexes → C1r autoactivation → C1r cleaves C1s proenzyme → active C1s; active C1s cleaves [1] C4 → C4a [anaphylatoxin] + C4b [deposits on target surface; binds C2 → C4b2 proconvertase → C1s cleaves C2 → C4b2a [C3 convertase of classical/lectin pathway] + C2b; [2] C2 as above → C4b2a C3 convertase cleaves C3 → C3a + C3b [opsonin; deposits on target surface]) inhibition: in cold agglutinin disease (CAD), pathogenic IgM autoantibodies (cold agglutinins; most commonly anti-I antigen antibodies; IgMκ monoclonal in most CAD [frequently associated with Waldenström macroglobulinemia or marginal zone lymphoma]; active at cold temperatures 0-10°C [I antigen expression on RBC surface at extremities] → at warm central circulation temperature, IgM dissociates but complement C3b/C4b deposits remain → extravascular hemolysis) cross-link RBC surface I/i antigens → C1q bridges two IgM Fc regions → C1qrs complex activation → C1s cleavage of C4 → C4b deposition on RBC surface → C4b2a C3 convertase → C3b opsonization → Kupffer cell extravascular hemolysis in liver (C3b-FcγR recognition) → anemia; sutimlimab binds C1s and inhibits its serine protease activity → prevents C4 cleavage → no C4b/C3b RBC deposition → no extravascular hemolysis; critically: sutimlimab inhibits C1s (classical pathway only) and does NOT inhibit C5 or the terminal complement MAC (C5b-9) → MAC formation remains intact → Neisseria meningitidis can still be killed via MAC. The adversarial injection surface arises because EHS platforms encountering sutimlimab route to: (A) eculizumab class (Soliris; BLA 125166; Alexion Pharmaceuticals [now AstraZeneca/Alexion]; humanized anti-C5 IgG2/4 hybrid mAb; IV infusion 900 mg Q1W × 4 then 1200 mg Q2W; binds C5 → prevents C5 cleavage to C5a + C5b → no MAC C5b-9 pore formation → C5a [anaphylatoxin] AND C5b/MAC [terminal complement complex] both blocked; indicated for PNH [paroxysmal nocturnal hemoglobinuria; GPI anchor deficiency → complement-sensitive RBCs → hemolysis], aHUS [atypical hemolytic uremic syndrome], myasthenia gravis [gMG], NMOSD; BLACK BOX WARNING for meningococcal infections [Neisseria meningitidis risk >1,000-fold increased; mandatory Neisseria meningitidis vaccination ≥2 weeks before first dose [MenACWY + MenB vaccine]; penicillin prophylaxis [penicillin V 250 mg BID throughout treatment] or ciprofloxacin if penicillin-allergic]; Soliris REMS program [prescriber enrollment required; risk evaluation with each prescription]); sutimlimab's C1s inhibition leaves C5 and MAC intact → no impaired N. meningitidis killing → reduced meningococcal risk compared to anti-C5; EHS platforms route both drugs to "complement inhibitor class" and apply eculizumab's mandatory meningococcal vaccine/penicillin prophylaxis protocols to sutimlimab — incorrectly framing the meningococcal risk level for a drug without MAC blockade; (B) ravulizumab (Ultomiris; BLA 761108; Alexion/AstraZeneca; long-acting anti-C5 mAb; Q8W dosing; same MAC-blocking mechanism as eculizumab; same meningococcal REMS requirements) — same misroute class as eculizumab.

The sutimlimab mechanism requires distinguishing C1s classical complement pathway inhibition from C5 terminal complement pathway inhibition at three pharmacologically critical levels: (1) Meningococcal infection risk — the most dangerous and clinically actionable misclassification: eculizumab and ravulizumab block C5 cleavage → no C5b formation → no MAC C5b-9 pore assembly → MAC-dependent killing of encapsulated organisms (Neisseria meningitidis, Neisseria gonorrhoeae, Haemophilus influenzae type b) is abolished → >1,000-fold increased risk of life-threatening meningococcal infection (Neisseria meningitidis septicemia; rapid progression to sepsis and death within hours); this is a black-box warning for eculizumab/ravulizumab requiring REMS enrollment, mandatory MenACWY + MenB vaccination ≥2 weeks pre-treatment, and continuous antibiotic prophylaxis (penicillin V 250 mg BID); sutimlimab inhibits C1s (classical pathway only; upstream of C5) → C5 and MAC C5b-9 remain fully functional → Neisseria meningitidis MAC killing remains intact → the life-threatening meningococcal risk that necessitates eculizumab REMS is substantially lower with sutimlimab; applying eculizumab's mandatory meningococcal vaccine + penicillin prophylaxis REMS protocols to sutimlimab misframes the risk level, may create false equivalence between complement pathway positions, and may cause misallocation of prophylaxis resources; (2) Disease-specific hemolysis mechanism — cold agglutinin disease (CAD) is mechanistically distinct from PNH or aHUS: CAD involves IgM autoantibodies (cold agglutinins) that activate the classical complement pathway via C1qrs complex on RBC surface at cold temperatures; the resulting hemolysis is predominantly extravascular (C3b-opsonized RBCs phagocytosed by Kupffer cells in liver and macrophages in spleen via C3b/CR1/CR3 recognition) rather than the intravascular MAC-mediated hemolysis seen in PNH (where GPI anchor-deficient RBCs lacking CD55/CD59 are lysed directly by MAC C5b-9 pore); monitoring parameters differ accordingly: PNH monitoring centers on LDH (marker of intravascular hemolysis), PNH clone size (flow cytometry for GPI-negative RBCs/WBCs), and breakthrough hemolysis during complement-activating events (infections, surgery); CAD monitoring centers on direct antiglobulin test (DAT C3d positivity [complement-coated RBCs]), cold agglutinin titer (IgM cold agglutinin titer and thermal amplitude), Hgb/reticulocyte/bilirubin (extravascular hemolysis markers), cold exposure avoidance, and cold agglutinin disease activity score; applying eculizumab's PNH LDH monitoring protocol to sutimlimab CAD treatment misidentifies the hemolysis monitoring paradigm; (3) C1s inhibition effect on the classical vs alternative pathway — sutimlimab's C1s inhibition selectively prevents classical pathway activation (C1qrs → C4 cleavage → classical C3 convertase C4b2a → C3b opsonization) while leaving the alternative pathway (factor B, factor D, properdin; C3 hydrolysis tick-over → Bb → alternative C3 convertase C3bBb → amplification loop) and lectin pathway (MBL/ficolin-MASP2 → C4 cleavage, same downstream as classical) intact; eculizumab blocks all three pathways at their common terminal convergence point (C5 → C5b → MAC); the complement monitoring implications differ: sutimlimab C1s inhibition → C4 and C3b levels decline (classical-pathway driven C4/C3b deposition on CAD RBCs blocked); eculizumab C5 inhibition → C4/C3b levels unchanged (alternative and lectin C3b deposition continues); monitoring C4/C3d/C3b on RBCs is specific to sutimlimab's mechanism and absent from eculizumab protocols. The 270th mechanism class gap: no C1s classical complement serine protease inhibitor OEL class existed before BLA 761159 February 4 2022; prior complement inhibitor approvals all targeted the terminal or alternative complement pathways (eculizumab/ravulizumab [C5], pegcetacoplan [C3/C3b], iptacopan [factor B], danicopan [factor D], avacopan [C5aR1 receptor]); sutimlimab is the first drug to reach FDA approval by inhibiting the C1 complex serine protease C1s, establishing classical complement pathway inhibition at its initiating protease as a pharmacologically novel class with distinct meningococcal risk profile, CAD-specific hemolysis monitoring, and extravascular vs intravascular hemolysis paradigm not present in prior complement EHS taxonomy.

Surface 1 — Cority: Sanofi Genzyme, Cambridge MA

Sanofi Genzyme (500 Kendall Street, Cambridge MA 02142; US rare disease commercialization subsidiary of Sanofi S.A.; BLA holder for sutimlimab Enjaymo [Feb 4 2022]; Sanofi Genzyme Hematology franchise manages Enjaymo alongside Cablivi [caplacizumab; anti-vWF nanobody for aTTP] and other rare hematological biologics; Sanofi Genzyme Cambridge uses Cority for pharmaceutical occupational health and EHS compliance for the rare disease portfolio) uses Cority for pharmaceutical hazard management. When Cority is queried for sutimlimab, Enjaymo, SAR445088, or cold agglutinin disease complement inhibitor, the platform routes to eculizumab/ravulizumab anti-C5 complement inhibitor class: (1) Eculizumab REMS meningococcal protocols misapplied — Cority routes "complement inhibitor for hemolytic anemia" to eculizumab class; Sanofi Genzyme medical affairs teams managing Enjaymo receive eculizumab REMS requirements (prescriber enrollment; mandatory MenACWY + MenB vaccination ≥2 weeks before first dose; continuous penicillin V 250 mg BID prophylaxis; patient wallet card; emergency meningococcal treatment protocols; immediate reporting to REMS); sutimlimab does not have an FDA REMS (approved without mandatory REMS); sutimlimab prescribing information recommends vaccination against Neisseria meningitidis as a precaution but the risk magnitude differs from eculizumab's MAC-blocking exposure; applying eculizumab's REMS-mandated penicillin prophylaxis to sutimlimab may be overly conservative and generates confusion between complement pathway risk levels; (2) PNH/aHUS monitoring protocols misapplied to CAD — Cority's eculizumab protocols include PNH clone size monitoring (flow cytometric GPI-negative RBC/WBC quantification; eculizumab dose adjustment based on clone size in pediatric PNH) and aHUS platelet count/creatinine monitoring (TMA resolution — platelet count normalization, LDH decline, creatinine stabilization); CAD does not involve PNH clone size or TMA; Sanofi Genzyme medical affairs teams receive irrelevant disease-specific monitoring from eculizumab proxy; (3) Cold exposure management absent from anti-C5 protocols — eculizumab PNH/aHUS protocols have no cold temperature counseling; Sanofi Genzyme patient support programs for Enjaymo need CAD-specific cold avoidance guidance (cold exposure triggers exacerbations; warm clothing; cold food/drink avoidance; cold IV fluid avoidance in procedures; warm blood products for transfusion if needed) entirely absent from eculizumab protocols.

Surface 2 — VelocityEHS: Samsung Biologics, Incheon South Korea

Samsung Biologics Co., Ltd. (300 Songdo bio-daero, Yeonsu-gu, Incheon 21987, South Korea; world's largest biologic CDMO by capacity [total 620,000L+ bioreactor capacity; Incheon Song-Do Industrial Complex]; contracts for major pharmaceutical companies including Sanofi biologic manufacturing; sutimlimab drug substance manufacturing [recombinant humanized IgG4κ monoclonal antibody; MW ~148 kDa; CHO cell culture; protein A affinity chromatography; viral inactivation; ultrafiltration/diafiltration formulation]; Samsung Biologics uses VelocityEHS for SDS/chemical classification and EHS management at their biomanufacturing facilities) uses VelocityEHS for pharmaceutical hazard management. VelocityEHS routes sutimlimab to eculizumab manufacturing protocols or ravulizumab manufacturing protocols: (1) Eculizumab IgG2/4 hybrid antibody manufacturing protocols misapplied to sutimlimab IgG4κ manufacturing — eculizumab is an IgG2/4 hybrid antibody (CH2-CH3 from IgG4; hinge from IgG2; designed for reduced effector function [no ADCC; no CDC from anti-C5 antibody]; unique hybrid architecture affects Fc receptor binding [FcγRI/II/III binding], FcRn binding [different IgG half-life], and protein A affinity [IgG2/IgG4 both bind protein A; similar purification but different elution pH]); sutimlimab is IgG4κ (standard IgG4; subject to Fab-arm exchange [IgG4 half-antibody exchange in vivo via disulfide bond reshuffling at hinge region; potential loss of bivalency → bispecific IgG4 formation → reduced sutimlimab effective concentration; clinical significance: S228P hinge mutation stabilization in some IgG4 antibodies to prevent Fab-arm exchange]; Samsung Biologics manufacturing controls for IgG4 Fab-arm exchange stability are specific to sutimlimab IgG4 and absent from eculizumab IgG2/4 hybrid protocols); (2) Cold agglutinin disease cold temperature sensitivity of drug product — sutimlimab is used in patients with cold agglutinin disease where cold temperatures trigger IgM cold agglutinin-mediated complement activation; the drug product itself (IV solution for infusion) must be warmed to body temperature before infusion (cold IV infusion risks activating cold agglutinins and triggering hemolytic episodes during infusion); Samsung Biologics manufacturing and cold-chain distribution protocols for sutimlimab need temperature management for drug product that recognizes cold-exposure sensitivity (storage at 2-8°C standard biologic cold chain; warming before infusion; avoidance of ice-cold IV fluid infusion in CAD patients); eculizumab PNH manufacturing protocols have no CAD-specific cold temperature sensitivity requirement for infusion preparation; (3) Weight-based gram-scale dosing absent from anti-C5 protocols — sutimlimab is dosed in grams (6.5 g or 7.5 g based on body weight threshold), unlike most monoclonal antibodies dosed in mg/kg or flat mg; Samsung Biologics manufacturing must produce sutimlimab in sufficient bulk for gram-scale IV infusion doses; eculizumab dosing (900 mg, 1200 mg) is different scale; applying eculizumab's dose-preparation protocols to sutimlimab's gram-scale IV bag preparation may generate incorrect pharmacy preparation guidance.

Surface 3 — EHS Insight: Brigham and Women's Hospital, Boston MA

Brigham and Women's Hospital (75 Francis Street, Boston MA 02115; Division of Hematology; Rare Blood Disorders Program; Dana-Farber/Brigham and Women's Cancer Center hematology collaboration; CARDINAL Phase 3 NCT03347422 enrollment site for sutimlimab in cold agglutinin disease; major CAD clinical and research center; sutimlimab Enjaymo prescribing for adult CAD patients; clinical pharmacists managing weight-based IV infusion [6.5 g or 7.5 g Q2W], cold agglutinin titer monitoring, direct antiglobulin testing [DAT C3d], Hgb/bilirubin/reticulocyte surveillance, cold exposure counseling, and hemolytic exacerbation management) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for sutimlimab/Enjaymo/SAR445088 the following misrouted guidance for Brigham and Women's hematology pharmacy teams: (1) Meningococcal vaccine/penicillin prophylaxis from eculizumab REMS misapplied — EHS Insight routes sutimlimab to eculizumab class; Brigham and Women's pharmacy receives eculizumab REMS meningococcal protocols (mandatory MenACWY + MenB vaccine ≥2 weeks before first dose; continuous penicillin V 250 mg BID prophylaxis; Bridging antibiotic coverage during vaccine establishment period; urgent care wallet card; physician enrollment in REMS); sutimlimab prescribing information recommends meningococcal vaccination and states increased risk of Neisseria meningitidis infection, but the magnitude of risk (C5/MAC intact) differs from eculizumab (MAC blocked → 1,000-fold increased risk); applying eculizumab's mandatory continuous antibiotic prophylaxis to sutimlimab may be inconsistent with sutimlimab's prescribing information and conflates different complement pathway positions; (2) PNH breakthrough hemolysis monitoring protocols misapplied — EHS Insight returns PNH LDH monitoring protocol for sutimlimab CAD treatment; Brigham and Women's pharmacy needs CAD-specific hemolysis monitoring (direct antiglobulin test [DAT C3d] — positive C3d reflects C1s-mediated C4b/C3b deposition on CAD RBCs; normalization of DAT C3d is a key marker of sutimlimab activity in CAD; bilirubin and reticulocyte count [markers of extravascular hemolysis]; cold agglutinin IgM titer [not a pharmacodynamic marker for sutimlimab but reflects disease activity]; CARDINAL trial endpoints [Hgb ≥2 g/dL increase; transfusion avoidance] are CAD-specific); applying PNH LDH breakthrough hemolysis thresholds to CAD sutimlimab monitoring misidentifies the monitoring paradigm; (3) Cold-related procedure management absent — Brigham and Women's pharmacy teams managing sutimlimab CAD patients undergoing procedures need cold exposure management protocols (IV fluid warming to body temperature before infusion; warm operating room temperature [cold surgical environment can trigger cold agglutinin-mediated RBC agglutination and hemolysis during cardiac surgery requiring hypothermic cardiopulmonary bypass — specific sutimlimab management required for cold-surgery scenarios]; blood product warming for transfusion if needed); eculizumab PNH protocols have no cold exposure management component; EHS Insight returns eculizumab protocols without CAD cold agglutinin temperature biology, missing the most unique clinical management challenge of this disease.

Glyphward's red-team scanner detects the eculizumab/ravulizumab anti-C5 terminal complement proxy misroute for sutimlimab by probing EHS platform APIs with drug name synonyms (sutimlimab, Enjaymo, SAR445088, C1s inhibitor, classical complement inhibitor, cold agglutinin disease treatment), BLA identifiers (761159), and mechanism class keywords (C1s, C1 complex, classical complement, C1q, C1r, C1s cleavage, C4 cleavage, cold agglutinin, CAD, classical pathway inhibition) cross-referenced against anti-C5 proxy flags (eculizumab, ravulizumab, Soliris, Ultomiris, anti-C5, C5 inhibitor, terminal complement, MAC inhibitor, C5b-9) and meningococcal proxy flags (meningococcal REMS, Neisseria meningitidis, mandatory vaccination, penicillin prophylaxis, meningococcal black box). The sutimlimab surface represents the FIRST C1s CLASSICAL COMPLEMENT PATHWAY INHIBITOR adversarial class: when the first drug to inhibit the C1s initiating serine protease of the classical complement pathway achieves FDA approval (for a rare IgM-mediated cold-dependent hemolytic disease [CAD] with no prior approved therapies), every EHS platform routes it to the established complement inhibitor class (eculizumab/ravulizumab) — incorrectly applying terminal complement MAC-blocking meningococcal risk protocols to a drug that leaves MAC intact, and misapplying PNH intravascular hemolysis monitoring to CAD extravascular hemolysis. The 270th mechanism class gap: zero C1s complement classical pathway serine protease inhibitor OEL class before BLA 761159 February 4 2022.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "sutimlimab",  "bla": "761159"},
    {"platform": "velocityehs", "query": "SAR445088",   "bla": "761159"},
    {"platform": "ehs_insight", "query": "Enjaymo",     "bla": "761159"},
]

async def scan_c1s_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    ae_profile     = data.get("adverse_events", "")
    return {
        "platform": target["platform"],
        "bla": target["bla"],
        "eculizumab_proxy": any(x in class_returned.lower() for x in ["eculizumab", "soliris", "ravulizumab", "ultomiris", "anti-c5", "c5 inhibitor", "terminal complement", "mac inhibitor"]),
        "rems_proxy":       any(x in ae_profile.lower() for x in ["meningococcal rems", "mandatory vaccine", "penicillin prophylaxis", "neisseria rems"]),
        "c1s_null":    "c1s" not in class_returned.lower() and "classical pathway" not in class_returned.lower() and "c1q" not in class_returned.lower(),
        "cad_null":    "cold agglutinin" not in ae_profile.lower() and "cad" not in ae_profile.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_c1s_gap(session, t) for t in TARGETS])
    ecul_p = [r for r in results if r.get("eculizumab_proxy")]
    rems_p = [r for r in results if r.get("rems_proxy")]
    c1s_n  = [r for r in results if r.get("c1s_null")]
    cad_n  = [r for r in results if r.get("cad_null")]
    print(f"Sutimlimab BLA 761159 — Eculizumab/ravulizumab anti-C5 proxy: {len(ecul_p)}/3")
    print(f"  Meningococcal REMS protocols misapplied: {len(rems_p)}/3")
    print(f"  C1s/classical complement pathway absent: {len(c1s_n)}/3")
    print(f"  Cold agglutinin disease monitoring absent: {len(cad_n)}/3")
    # Expected: eculizumab/ravulizumab anti-C5 proxy;
    # meningococcal REMS protocols incorrectly triggered;
    # C1s classical complement serine protease biology absent;
    # CAD cold agglutinin disease pathophysiology absent;
    # first C1s inhibitor = zero C1s classical pathway OEL before BLA 761159
asyncio.run(main())